Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: i-node who wrote (498853)	7/28/2009 12:15:26 PM
From: longnshort	Respond to of 1576160

Chris Dodd's Wife Financially Tied to Health Companies Published by Lindsay Renick Mayer on July 17, 2009 3:23 PM \| Permalink \| Comments (0) CJD_front.jpgJackie Clegg Dodd, the wife of Sen. Chris Dodd (D-Conn.), sits on the board of four health organizations from which she collected at least $4,000 in director's fees in 2008, according to Dodd's recently released personal financial disclosure reports. (Dodd had filed for an extension to the May 15 deadline.) Those groups include: * Assisted living facility and retirement community, Brookdale Senior Living, Inc. * Drug maker Cardiome Pharma Corp. * Drug maker Javelin Pharma Inc. * Non-profit Public Welfare Foundation Dodd's wife also sits on the board of Pear Tree Pharmaceutical, which gave her less than $1,000 in director's fees, according to the senator's disclosure reports. Dodd is filling in for Sen. Edward Kennedy (D-Mass.) -- absent as he battles brain cancer -- at the helm of the Senate Health, Education, Labor and Pensions Committee. This week, under Dodd's leadership, the panel passed its own health care reform plan, including a public health insurance option. In addition to the money Dodd's wife has collected for her service to these organizations, she also reported holding between $51,000 and $122,000 in these groups' stock options. The stock options are likely part of her compensation as a director, but they appear to be worth very little at the moment unless the stock prices rise.